This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Sep 2;385(10):948-950.

doi: 10.1056/NEJMe2110953.

Immune Thrombocytopenia Treatment

Paula H B Bolton-Maggs¹, James N George¹

Affiliations

Affiliation

¹ From the Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK (P.H.B.B.-M.); and the Departments of Epidemiology and Biostatistics, and Medicine, University of Oklahoma Health Sciences Center, Oklahoma City (J.N.G.).

PMID: 34469652
DOI: 10.1056/NEJMe2110953

Editorial

Immune Thrombocytopenia Treatment

Paula H B Bolton-Maggs et al. N Engl J Med. 2021.

. 2021 Sep 2;385(10):948-950.

doi: 10.1056/NEJMe2110953.

Authors

Paula H B Bolton-Maggs¹, James N George¹

Affiliation

¹ From the Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK (P.H.B.B.-M.); and the Departments of Epidemiology and Biostatistics, and Medicine, University of Oklahoma Health Sciences Center, Oklahoma City (J.N.G.).

PMID: 34469652
DOI: 10.1056/NEJMe2110953

No abstract available

PubMed Disclaimer

Comment on

Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia.
Bradbury CA, Pell J, Hill Q, Bagot C, Cooper N, Ingram J, Breheny K, Kandiyali R, Rayment R, Evans G, Talks K, Thomas I, Greenwood R. Bradbury CA, et al. N Engl J Med. 2021 Sep 2;385(10):885-895. doi: 10.1056/NEJMoa2100596. N Engl J Med. 2021. PMID: 34469646 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.